Off-Label Use of Letermovir as Preemptive Anti-Cytomegalovirus Therapy in a Pediatric Allogeneic Peripheral Blood Stem Cell Transplant
| Autor: | Giulia Piccirilli, Riccardo Masetti, Liliana Gabrielli, Angela Chiereghin, Arcangelo Prete, Tiziana Lazzarotto, Stefano Fanti, Maura Fois, Gabriele Turello, Michele Borghi, Tamara Belotti, Eva Caterina Borgatti, Nicola Fraccascia |
|---|---|
| Přispěvatelé: | Chiereghin A, Belotti T, Borgatti EC, Fraccascia N, Piccirilli G, Fois M, Borghi M, Turello G, Gabrielli L, Masetti R, Prete A, Fanti S, Lazzarotto T. |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Foscarnet 030106 microbiology Congenital cytomegalovirus infection gcv-resistant cmv Case Report Off-label use off-label letermovir use lcsh:Infectious and parasitic diseases 03 medical and health sciences chemistry.chemical_compound Letermovir 0302 clinical medicine pediatric allogeneic peripheral blood stem cell transplant medicine intolerance to fos Pharmacology (medical) lcsh:RC109-216 030212 general & internal medicine Adverse effect Pharmacology business.industry virus diseases medicine.disease Infectious Diseases chemistry Viral replication Immunology business Viral load Cidofovir medicine.drug |
| Zdroj: | Infection and Drug Resistance, Vol Volume 14, Pp 1185-1190 (2021) Infection and Drug Resistance |
| ISSN: | 1178-6973 |
| Popis: | Angela Chiereghin,1,2 Tamara Belotti,3 Eva Caterina Borgatti,4 Nicola Fraccascia,5 Giulia Piccirilli,6 Maura Fois,3 Michele Borghi,4 Gabriele Turello,4 Liliana Gabrielli,6 Riccardo Masetti,3 Arcangelo Prete,3 Stefano Fanti,5 Tiziana Lazzarotto4 1Section of Microbiology, Department of Specialized, Experimental, and Diagnostic Medicine, University of Bologna, Bologna, Italy; 2Department of Public Health, Local Health Authority of Bologna, Bologna, Italy; 3Pediatric Oncology and Haematology Unit “Lalla Seragnoli”, Department of Pediatrics, IRCCS St. Orsola Polyclinic, University of Bologna, Bologna, Italy; 4Microbiology Unit, Department of Specialized, Experimental, and Diagnostic Medicine, IRCCS St. Orsola Polyclinic, University of Bologna, Bologna, Italy; 5Nuclear Medicine Unit, Department of Specialized, Experimental, and Diagnostic Medicine, IRCCS St. Orsola Polyclinic, University of Bologna, Bologna, Italy; 6Microbiology Unit, IRCCS St. Orsola Polyclinic, University of Bologna, Bologna, ItalyCorrespondence: Tiziana LazzarottoMicrobiology Unit, Department of Specialized, Experimental, and Diagnostic Medicine, IRCCS St. Orsola Polyclinic, University of Bologna, via Massarenti 9, Bologna, 40138, ItalyTel +39 0512143360Fax +39 0512143514Email tiziana.lazzarotto@unibo.itAbstract: Despite the effectiveness of the currently available antiviral drugs in treating cytomegalovirus (CMV) infection, high rates of adverse effects are associated with their use. Moreover, a problem of increasing importance is the emergence of drug-resistant CMV infection. Here, we describe the first case of off-label use of letermovir (LMV) as preemptive antiviral therapy, in a pediatric allogeneic peripheral blood stem cell transplant recipient with ganciclovir-resistant CMV infection who was intolerant to foscarnet and unable to achieve viral clearance after seven doses of cidofovir. After the administration of LMV, a gradual reduction in viral load was observed and within 6 weeks of LMV treatment, after more than 6 months of positive CMV-DNAemia, the patient cleared the infection. No adverse effects associated with LMV were observed during treatment. In this pediatric study case, the off-label use of LMV for the treatment of CMV infection has been well tolerated and proved to be effective in leading to the suppression of viral replication.Keywords: pediatric allogeneic peripheral blood stem cell transplant, GCV-resistant CMV, intolerance to FOS, off-label letermovir use |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|